AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17635756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multiple risk factor modification (targeting hypercholesterolaemia, hyperhomocysteinaemia, anaemia and disordered bone mineral metabolism)
Number of subjects: 200
Study 17635756 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 16139403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact limb (amputee)
Number of subjects: 9
Study 12391370 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0
Study 12391370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9973590 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic fitness program using bicycle ergometry
Number of subjects: 82
Study 9973590 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 7547855 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid fibre (LF) 300 ml
Number of subjects: 17
Study 7547855 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 17
Study 7547855 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid fibre (LF)
Number of subjects: 17
Study 2127790 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐interferon (5 mega units thrice weekly for 2 months, then 1.5 mega units until the eighteenth month)
Number of subjects: 30
Study 2127790 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐interferon
Number of subjects: 30
Study 2127790 — intervention group
Group type: COMPARATOR
Intervention: Control group (without treatment)
Number of subjects: 30
Study 369926 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 111
Study 369926 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 111
Study 31715582 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized F‐V profile‐based training (2 sessions over 9 weeks)
Number of subjects: 46
Study 31715582 — intervention group
Group type: COMPARATOR
Intervention: Standardized training regimen (control group, 10 participants)
Number of subjects: 46
Study 31487208 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 498
Study 31487208 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 498
Study 31487208 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 498
Study 28784841 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-specific written sign-out template
Number of subjects: 0
Study 28784841 — intervention group
Group type: COMPARATOR
Intervention: Usual ICU sign-out
Number of subjects: 0
Study 25852206 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+DHA (3.9 g/day)
Number of subjects: 31
Study 25852206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23298459 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional sets emphasizing concussion history or gender (specifics on dosage and duration not available)
Number of subjects: 0
Study 23298459 — intervention group
Group type: COMPARATOR
Intervention: Neutral instructions (control group)
Number of subjects: 0
Study 23298459 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender stereotype condition (specifics on dosage and duration not available)
Number of subjects: 0
Study 21784390 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting stent (ZES)
Number of subjects: 476
Study 21784390 — intervention group
Group type: COMPARATOR
Intervention: Driver bare-metal stent (BMS)
Number of subjects: 476
Study 21784390 — intervention group
Group type: COMPARATOR
Intervention: Endeavor zotarolimus-eluting stent (ZES) vs Driver bare-metal stent (BMS)
Number of subjects: 476
Study 19270260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 151
Study 19270260 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study 17383013 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of EPA and DHA
Number of subjects: 105
Study 17383013 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA and EPA
Number of subjects: 105
Study 17383013 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 105
Study 17383013 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐LNA
Number of subjects: 105
Study 15172862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine lidocaine (3 mL of buffered 2% lidocaine solution)
Number of subjects: 127
Study 15172862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 127
Study 11510780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurization rate at 5 cmH2O
Number of subjects: 10
Study 11510780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurization rate at 15 cmH2O
Number of subjects: 10
Study 11510780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest pressurization rate
Number of subjects: 10
Study 11510780 — intervention group
Group type: EXPERIMENTAL
Intervention: Other pressurization rates (excluding lowest)
Number of subjects: 10
Study 11510780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas exchange
Number of subjects: 10
Study 9928572 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell support
Number of subjects: 1
Study 9928572 — intervention group
Group type: COMPARATOR
Intervention: Standard dose treatment
Number of subjects: 1
Study 7830545 — intervention group
Group type: EXPERIMENTAL
Intervention: Degni‐Cordeiro's microsurgical indirect lymphatico‐venous shunt (L.V.S.) surgery
Number of subjects: 36
Study 7830545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasciotomies along the posterior aspect of the forearm
Number of subjects: 36
Study 7830545 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple fasciotomies alone
Number of subjects: 36
Study 7830545 — intervention group
Group type: EXPERIMENTAL
Intervention: Kondoleon's partial superficial lymphangectomy
Number of subjects: 36
Study 7830545 — intervention group
Group type: EXPERIMENTAL
Intervention: Servelle's total superficial lymphangectomy
Number of subjects: 36
Study 7830545 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 36
Study 3061400 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent clinical follow-ups without changing dietary intake of protein
Number of subjects: 0
Study 3061400 — intervention group
Group type: COMPARATOR
Intervention: Standard care (implied control)
Number of subjects: 0
Study 29709643 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral food challenge (OFC)
Number of subjects: 120
Study 29709643 — intervention group
Group type: EXPERIMENTAL
Intervention: CD63 ratio
Number of subjects: 120
Study 29709643 — intervention group
Group type: EXPERIMENTAL
Intervention: History of exercise-induced asthma
Number of subjects: 120
Study 29709643 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1/FVC ratio
Number of subjects: 120
Study 28933961 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β-Estradiol (E2), 0.72 mg transdermally for 2-8 weeks
Number of subjects: 58
Study 28933961 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β-Estradiol (E2), 0.62 mg and norethindrone acetate (P), 2.70 mg for 3-16 weeks
Number of subjects: 58
Study 28933961 — intervention group
Group type: EXPERIMENTAL
Intervention: Estra-1,3,5(10)-triene-3,16α, 17β-triol (E3) vaginal tablet 0.5 mg per month five times
Number of subjects: 58
Study 28933961 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 58
Study 25898050 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training
Number of subjects: 180
Study 25898050 — intervention group
Group type: COMPARATOR
Intervention: Parent education
Number of subjects: 180
Study 23163714 — intervention group
Group type: EXPERIMENTAL
Intervention: Active manipulation group (AAT with contingency between arm movement and picture type)
Number of subjects: 0
Study 23163714 — intervention group
Group type: COMPARATOR
Intervention: Control group (AAT without contingency)
Number of subjects: 0
Study 21247563 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed women
Number of subjects: 132
Study 21247563 — intervention group
Group type: COMPARATOR
Intervention: Nonworking women
Number of subjects: 132
Study 18440921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (30 mg)
Number of subjects: 24
Study 18440921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone (15 mg)
Number of subjects: 24
Study 18440921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16529577 — intervention group
Group type: EXPERIMENTAL
Intervention: Testogel (5 g containing 50 mg testosterone, daily) for 4 weeks, followed by tadalafil (20 mg, twice a week)
Number of subjects: 69
Study 16529577 — intervention group
Group type: EXPERIMENTAL
Intervention: Testogel (5 g containing 50 mg testosterone, daily) for 10 weeks before adjunctive therapy with tadalafil
Number of subjects: 69
Study 16529577 — intervention group
Group type: EXPERIMENTAL
Intervention: Testogel and tadalafil combination therapy
Number of subjects: 69
Study 14729656 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 801
Study 14729656 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 801
Study 11348940 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with COPD
Number of subjects: 4035
Study 11348940 — intervention group
Group type: COMPARATOR
Intervention: Healthy smokers
Number of subjects: 4035
Study 11348940 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups of smokers
Number of subjects: 4035
Study 9236443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber rate-responsive pacemaker therapy
Number of subjects: 107
Study 9236443 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 107
Study 9236443 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 107
Study 7958108 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA for insulin antibodies (IA) in IDDM patients
Number of subjects: 58
Study 7958108 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA for insulin antibodies (IA) in NIDDM patients treated with insulin
Number of subjects: 58
Study 7958108 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA for insulin autoantibodies (IAA) in NIDDM patients without insulin therapy
Number of subjects: 58
Study 7958108 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA for insulin autoantibodies (IAA) in Graves' disease patients
Number of subjects: 58
Study 7958108 — intervention group
Group type: COMPARATOR
Intervention: RBA for insulin autoantibodies (IAA) in NIDDM patients without insulin therapy
Number of subjects: 58
Study 7958108 — intervention group
Group type: COMPARATOR
Intervention: RBA for insulin autoantibodies (IAA) in Graves' disease patients
Number of subjects: 58
Study 3309444 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Acyclovir eye ointment
Number of subjects: 28
Study 3309444 — intervention group
Group type: COMPARATOR
Intervention: 3% Adenosine Arabinoside eye ointment
Number of subjects: 28
Study 29067717 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic augmented skin surface generation with tactile mask
Number of subjects: 0
Study 29067717 — intervention group
Group type: COMPARATOR
Intervention: Visual only interface
Number of subjects: 0
Study 28007108 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens group (n=54)
Number of subjects: 108
Study 28007108 — intervention group
Group type: COMPARATOR
Intervention: IOL group (n=54)
Number of subjects: 108
Study 23600695 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback provided on 0%, 50%, or 100% of the trials
Number of subjects: 0
Study 23600695 — intervention group
Group type: EXPERIMENTAL
Intervention: Stacked presentations
Number of subjects: 0
Study 23600695 — intervention group
Group type: COMPARATOR
Intervention: No feedback provided during blocks 5 and 6
Number of subjects: 0
Study 23600695 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence ratings
Number of subjects: 0
Study 23276775 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided intervention (10 session workbook, 10 biweekly, 8 monthly, and 6 bimonthly phone coaching calls, bimonthly weight graphs, tailored letters)
Number of subjects: 419
Study 23276775 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed intervention (workbook and two calls)
Number of subjects: 419
Study 23276775 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided intervention
Number of subjects: 419
Study 19956091 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemin (3 mg/kg intravenously in 25% albumin)
Number of subjects: 10
Study 19956091 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin alone)
Number of subjects: 10
Study 19083412 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified fermented milk beverage supplemented with Lactobacillus acidophilus (3 mg iron per 80 mL)
Number of subjects: 190
Study 19083412 — intervention group
Group type: COMPARATOR
Intervention: Control group (fermented milk beverage without Lactobacillus acidophilus)
Number of subjects: 190
Study 19083412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 190
Study 16884986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonheparinized blood
Number of subjects: 27
Study 16884986 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized blood
Number of subjects: 27
Study 16884986 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo heparinization
Number of subjects: 27
Study 16884986 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 12939317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate (0.6 mol/L)
Number of subjects: 12
Study 10092890 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant arteriovenous fistula (AVF) included in the operative procedure (n = 48)
Number of subjects: 87
Study 10092890 — intervention group
Group type: COMPARATOR
Intervention: Control group without AVF (n = 41)
Number of subjects: 87
Study 7747212 — intervention group
Group type: EXPERIMENTAL
Intervention: Latin American refugees
Number of subjects: 1623
Study 7747212 — intervention group
Group type: EXPERIMENTAL
Intervention: South European labour migrants
Number of subjects: 1623
Study 7747212 — intervention group
Group type: EXPERIMENTAL
Intervention: South Europeans
Number of subjects: 1623
Study 7747212 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social class, age 45-64 years, poor social network, not feeling secure in daily life, not taking regular exercise
Number of subjects: 1623
Study 7747212 — intervention group
Group type: COMPARATOR
Intervention: Finnish and Swedish controls
Number of subjects: 1623
Study 2502437 — intervention group
Group type: EXPERIMENTAL
Intervention: hFSH
Number of subjects: 20
Study 2502437 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 20
Study 3746 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D preparation
Number of subjects: 25
Study 3746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30943939 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive intervention group combining a website (STAK-D) and a PolarActive activity watch (PAW) alongside usual care
Number of subjects: 49
Study 30943939 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 49
Study 28363704 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-administered version of PM-3D4D
Number of subjects: 262
Study 28363704 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered version of PM-3D4D
Number of subjects: 262
Study 25031222 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 121
Study 25031222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 25031222 — intervention group
Group type: EXPERIMENTAL
Intervention: THC preceded by cognitive awareness condition
Number of subjects: 121
Study 23691266 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg oral, 1 month before surgery)
Number of subjects: 30
Study 23691266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 21551996 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education (including lecture, skill training, team-based practice, and debriefing)
Number of subjects: 50
Study 21551996 — intervention group
Group type: COMPARATOR
Intervention: Traditional education (control group)
Number of subjects: 50
Study 19411800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) devices
Number of subjects: 43
Study 19411800 — intervention group
Group type: COMPARATOR
Intervention: Knee and thigh length compression stockings (CS)
Number of subjects: 43
Study 18236764 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Chinese and Western medicine (ICWM) protocol
Number of subjects: 606
Study 18236764 — intervention group
Group type: COMPARATOR
Intervention: Western medicine plus placebo
Number of subjects: 606
Study 15545307 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg R411 as a single oral dose
Number of subjects: 132
Study 15545307 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg RO0270608 as an intravenous infusion
Number of subjects: 132
Study 15545307 — intervention group
Group type: COMPARATOR
Intervention: Single oral doses of R411 (10-1200 mg)
Number of subjects: 132
Study 15545307 — intervention group
Group type: COMPARATOR
Intervention: Repeated oral doses of R411 (50-900 mg) for up to 3 weeks
Number of subjects: 132
Study 11396759 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation (EBD)
Number of subjects: 180
Study 11396759 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 180
Study 9893692 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved blood glucose control
Number of subjects: 5102
Study 8289475 — intervention group
Group type: EXPERIMENTAL
Intervention: ETI (Etoposide 80 mg/m2, Thioguanine 100 mg/m2 twice a day on days 1-5, Idarubicin 15 mg/m2 on days 1-3)
Number of subjects: 51
Study 8289475 — intervention group
Group type: COMPARATOR
Intervention: TAD (Oral Thioguanine 100 mg/m2 twice a day on days 1-5, i.v. Cytarabine, Daunorubicin 60 mg/m2 on day 5)
Number of subjects: 51
Study 3301058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of streptokinase
Number of subjects: 533
Study 3301058 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in the coronary care unit
Number of subjects: 533
Study 29661905 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 40
Study 29661905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27475737 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid determination of methicillin resistance using real-time PCR
Number of subjects: 89
Study 27475737 — intervention group
Group type: COMPARATOR
Intervention: Control group without PCR results
Number of subjects: 89
Study 24897083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin (1200 mg single intravenous dose)
Number of subjects: 954
Study 24897083 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (twice daily for 7 to 10 days)
Number of subjects: 954
Study 22240281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at LI4
Number of subjects: 98
Study 22240281 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 98
Study 22240281 — intervention group
Group type: COMPARATOR
Intervention: Waiting group
Number of subjects: 98
Study 22240281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at LI4 (subgroup of 13 participants)
Number of subjects: 98
Study 20552165 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 149
Study 20552165 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 149
Study 18388226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionization smoke alarms
Number of subjects: 761
Study 18388226 — intervention group
Group type: COMPARATOR
Intervention: Photoelectric smoke alarms
Number of subjects: 761
Study 18349181 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron disintegrating tablets (ODT)
Number of subjects: 200
Study 18349181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 15224055 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary protractor bow appliance (MPBA) used for a mean period of 5 months in the DT group
Number of subjects: 120
Study 15224055 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary protractor bow appliance (MPBA) used for a mean period of 10 months in the MT group
Number of subjects: 120
Study 15224055 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 120
Study 11320369 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (400 to 800 mg daily)
Number of subjects: 36
Study 10322821 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaibao oral liquid (KABOL)
Number of subjects: 103
Study 10322821 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 103
Study 8494577 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 20 mg
Number of subjects: 29
Study 8494577 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 40 mg
Number of subjects: 29
Study 8494577 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 80 mg
Number of subjects: 29
Study 8494577 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 120 mg
Number of subjects: 29
Study 8494577 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 180 mg
Number of subjects: 29
Study 8494577 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 240 mg
Number of subjects: 29
Study 8494577 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 360 mg
Number of subjects: 29
Study 8494577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3115081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligosaccharides infusion (144 +/- 41.0 g/day)
Number of subjects: 14
Study 3115081 — intervention group
Group type: COMPARATOR
Intervention: Control (no oligosaccharides)
Number of subjects: 14